COMMUNIQUÉS West-GlobeNewswire

-
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
14/02/2024 -
10 Barrel Brewing Launches Pub Ice: a Refreshing Twist on ‘Cheap Fun’
14/02/2024 -
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
14/02/2024 -
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
14/02/2024 -
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
14/02/2024 -
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
14/02/2024 -
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
14/02/2024 -
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
14/02/2024 -
Evoke Pharma Announces Closing of $7.5 Million Public Offering
14/02/2024 -
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
14/02/2024 -
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
14/02/2024 -
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
14/02/2024 -
Microbix Reports Record Results for Q1 Fiscal 2024
14/02/2024 -
Shineco Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
14/02/2024 -
Healthcare Triangle Unveils New SaaS Solutions to Drive Digital Transformation and AI Integration in Healthcare
14/02/2024 -
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
14/02/2024 -
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14/02/2024 -
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
14/02/2024 -
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
14/02/2024
Pages